این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Journal of Pharmaceutical Care، جلد ۱۲، شماره ۱، صفحات ۶۰-۶۳
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Third Nerve Palsy: Rare Adverse Event following Covid-19 Vaccination
چکیده انگلیسی مقاله Drugs Controller General of India (DCGI) in April 2022 approved the emergency use authorisation of Corbevax and Covaxin COVID 19 vaccines in children. Corbevax is a protein subunit COVID 19 vaccine developed by Texas Children's Hospital.  Third nerve palsy is rarely reported following protein sub- unit COVID vaccines. We report a case of a 13-year-old male who presented to a tertiary care hospital with complaints of   giddiness, headache, diplopia and drooping of left eye within one hour of receiving Corbevax vaccine in school. He was subsequently diagnosed with third nerve palsy and treated with corticosteroids and lubricant eye drops. He recovered fully and was discharged after four days. Causality assessment as per World Health Organization (WHO) guidelines for the causality assessment of Adverse Events Following Immunization (AEFI) was consistent. Protein sub unit vaccines can rarely cause third nerve palsy.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Indira Deshmukh
MBBS PG 3


| Shreyas Burute
Associate Professor Deportment of Pharmacology Government Medical College Miraj


| Shraddha Pore
indiradeshmukh87@gmail.com


| Atmik Singh
indiradeshmukh87@gmail.com
نشانی اینترنتی https://jpc.tums.ac.ir/index.php/jpc/article/view/633
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات